Search
Search Results
-
Alectinib-induced rash unresponsive to desensitization: a case report and literature review
BackgroundSince the inception of targeted therapies in treating lung cancer, providers have had to be aware of a new host of side effects when...
-
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree...
-
A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib
PurposeIn exposure–response analyses of oral targeted anticancer agents, longitudinal plasma trough concentrations are often aggregated into a single...
-
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
The advent of next-generation sequencing (NGS) has allowed for the identification of novel therapeutic targets for patients with uncommon cancers. It...
-
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
BackgroundA modeling framework was previously developed to simulate overall survival (OS) using tumor growth inhibition (TGI) data from six...
